United States Patent 9,717,724: Scope, Claim Strength, and Patent Landscape for Gemcitabine-Post Metastatic Pancreatic Cancer Using Liposomal Irinotecan
What does US 9,717,724 claim, in practical terms?
US 9,717,724 claims a treatment method for metastatic pancreatic adenocarcinoma after progression on gemcitabine-based therapy, with an eligibility restriction tied to UTG1A1*28 genotype (claims require patients not homozygous* for UTG1A128), using a q2-week intravenous regimen** that combines:
- Liposomal irinotecan at 70 mg/m² irinotecan free base
- Leucovorin (l-form) at 200 mg/m² (often via 400 mg/m² (l+d) leucovorin to deliver that l-form dose)
- 5-fluorouracil at 2,400 mg/m²
The claims also lock in formulation and exposure parameters (liposome size, lipid composition, and PK targets like AUC0-∞ and Cmax, plus an irinotecan half-life metric in the patient).
Core regimen structure (claims 1, 11, 21, 22; and dependent claim refinements)
| Claim cluster |
Indication + setting |
Dose frequency |
Liposomal irinotecan administration |
Key combination doses |
| Claim 1 |
Metastatic pancreatic adenocarcinoma after progression on gemcitabine; *not homozygous UTG1A128** |
Every 2 weeks |
IV infusion (general timing in claim 1) |
70 mg/m² irinotecan free base + 200 mg/m² (l)-leucovorin + 2,400 mg/m² 5-FU |
| Claim 11 |
Same, but infusion over 90 minutes |
Every 2 weeks |
IV infusion over 90 min |
Same combination doses; adds AUC window for liposomal irinotecan |
| Claim 21 |
Metastatic pancreatic adenocarcinoma after progression on gemcitabine (no genotype requirement in the independent claim text) |
Every 2 weeks |
“intravenous infusion” (no explicit 90-min timing in the independent claim) |
70 mg/m² irinotecan free base + 5-FU + leucovorin |
| Claim 22 |
Same as claim 21, adds genotype requirement |
Every 2 weeks |
Infusion timing constrained in dependent claims |
Adds liposome size (~110 nm) and half-life (25.8 h) |
Absolute claim “tells” (what most directly narrows scope)
Across the claim set, the strongest narrowing elements are:
- *UTG1A128 genotype restriction** (in several versions of the method)
- Specific liposomal irinotecan PK windows (AUC0-∞ and Cmax ranges; also AUC0-28 in claim 16)
- Specific liposome size (~110 nm) and lipid composition (DSPC, cholesterol, PEG-derivatized phosphatidyl-ethanolamine; MPEG-2000-DSPE)
- Loading state: irinotecan encapsulated in aqueous space as sucrose octasulfate salt, gelated/precipitated state
- PK half-life in vivo: terminal elimination half-life ~25.8 hours and/or higher than free CPT-11 by at least 2-fold (claim 17)
How broad or narrow is the independent claim coverage?
The patent uses multiple independent method claim formulations. Coverage is best understood as a set of overlapping “boxes”. A competitor’s product or label change needs to exit at least one box to avoid literal infringement, but the claim structure also creates multiple paths to capture variants.
Independent-method structure and likely infringement touchpoints
| Independent claim |
Genotype requirement |
Indication framing |
Liposomal product constraints inside independent claim |
Timing constraint inside independent claim |
| Claim 1 |
Yes (not homozygous UTG1A1*28) |
Metastatic adenocarcinoma of pancreas |
Liposome composition/PK partially embedded via “antineoplastic therapy consisting of” (dependent claims add explicit formulation details; the independent includes the infusion and PK half-life 25.8 h) |
Not fixed in claim 1 |
| Claim 11 |
Same genotype |
Same |
Adds AUC0-∞ range “about 1091-1705” and uses infusion-over-90-min structure; also includes liposome details indirectly |
90 minutes |
| Claim 16 |
No genotype in the independent portion as written (but dependent claims do specify characteristics) |
Pancreatic cancer after gemcitabine; includes nanoparticle diameter 80-140 nm |
Requires nanoparticle (80-140 nm) and sets PK characteristics for AUC0-28 and/or Cmax |
Not tied to 90 min in independent claim 16 |
| Claim 21 |
Genotype not in the independent method text; later claim 22 adds it |
Metastatic adenocarcinoma of pancreas after gemcitabine progression |
Requires liposomal irinotecan but does not, in the independent text provided, repeat PK windows |
Not fixed in the independent |
Net effect: the patent is not a single-lane claim. It is a multi-track method patent where at least one independent claim can read across many real-world use patterns, while dependents tighten further for formulation and exposure.
What exactly must infringe for liposomal irinotecan to be “inside” the claims?
The claims define the liposomal entity through size, composition, and drug-carrier PK behavior. The dependent claim language matters because it gives explicit alternatives that can still satisfy coverage.
1) Liposome size and structure
- ~110 nm diameter (claims 7, 12, and claim 22 via “approximately 110 nm”)
- Unilamellar lipid bilayer vesicles (claim 6)
- “Irinotecan nanoparticles” in claim 16: 80-140 nm diameter, which is a broader size band that can capture variants while still remaining within a constrained nanoscale envelope.
2) Lipid composition and PEGylation
- DSPC, cholesterol, and MPEG-2000-DSPE (claims 9, 12, 18, and claim 24 via list form).
- PEG-derivatized phosphatidyl-ethanolamine appears as the PEGylated lipid component (claims 6, 7, 12, 18, 24).
3) Encapsulation and loading state
- Irinotecan encapsulated in an aqueous space containing irinotecan in gelated or precipitated state as the sucrose octasulfate salt (claims 8 and 15 and claim 24).
This is a manufacturing detail that is often absent from biosimilar-style analyses and becomes a key decision point for generic or follow-on formulations.
4) PK/exposure constraints: AUC and Cmax ranges
The claims set explicit plasma exposure bands for liposomal irinotecan:
- AUC0-∞:
- 1091-1705 [h·µg/mL] (claim 2)
- 1364 [h·µg/mL] (claim 3) (a single-point constraint)
- Cmax:
- 29-47 µg/mL (claim 4)
- 37 µg/mL (claim 5) (single-point constraint)
Claim 11 also uses AUC0-∞ about 1091-1705 [h·µg/mL] and ties it to infusion over 90 minutes.
Claim 16 introduces AUC0-28 as one of the selectable nanoparticle characteristics:
- AUC0-28 about 1091-1705 [h·µh/mL] (as written in the provided claim text; the unit formatting appears unusual but the numeric range is the operative constraint in the claim set you provided.)
5) In vivo terminal elimination half-life
- terminal elimination half-life in patient of 25.8 hours (claim 1, claim 19)
- at least about 2-fold higher than free CPT-11 (claim 17)
- Claim 20 adds SN-38 exposure behavior: SN-38 AUC increases less than proportionally with dose, a non-linear pharmacokinetic relationship that can be difficult to replicate accidentally.
How does leucovorin stereochemistry tighten scope?
The regimen requires leucovorin as the (l) form at 200 mg/m². The claims allow dosing via a prodrug-like presentation:
- Claim 10: 200 mg/m² (l)-form provided by administering 400 mg/m² of (l+d) leucovorin.
- Claim 13 and claim 18 repeat the same dosing conversion in other claim contexts.
This creates a compliance path for users who administer the commercially available mixture, while still anchoring infringement to the effective (l)-form requirement.
How do the claims cover dosing schedule and infusion time?
- Many independent method versions define dosing frequency as once every two weeks (claims 1, 11, 16, 21, 22).
- Claim 11 specifies administration of liposomal irinotecan over 90 minutes.
- Claim 23 specifies that, in claim 11, “each IV infusion of liposomal irinotecan” is administered over 90 minutes.
For a challenge, changing infusion duration might not avoid infringement if other independent claims omit the 90-minute constraint; however, it can help distinguish from claim 11/23-literal capture if exposure/PK constraints remain identical.
Where does claim 16 broaden into “nanoparticles” rather than “liposomes”?
Claim 16 is structurally distinct:
- It requires irinotecan nanoparticles with diameter 80-140 nm, administered as a single dose of 70 mg/m² irinotecan free base, combined with leucovorin and 5-FU.
- It includes selective characteristics, including AUC0-28 and Cmax (29-47 µg/mL).
The “single dose” language could collide with q2-week method framing depending on how the regimen is practiced, but the claim set as given still centers on the same combined therapy and the same q2-week cadence appears in claim 16’s independent statement (“once every two weeks”).
Key implication: a follow-on formulation that changes liposome identity but still hits the diameter and PK windows can fall into the claim 16 pathway even if it misses the ~110 nm “liposome” language in other dependents.
What is the likely patent landscape shape around these claims?
With only the claim text supplied, the landscape can be characterized by claim-type clustering, which is typically how US portfolios around combination-oncology products evolve. US 9,717,724 is a method-of-treatment patent with product-property hooks (PK exposure and formulation attributes). That pattern usually sits downstream of:
- earlier composition/formulation patents on the liposomal irinotecan carrier,
- and clinical regimen patents tying dosing frequency and combination partners (5-FU/leucovorin) to a defined patient population.
Landscape map (claim-type analysis, not litigation history)
| Patent layer (typical for this product class) |
What it protects |
How your claims behave |
Practical attack/defense axis |
| Composition/formulation |
Lipid composition, vesicle type, loading chemistry |
Your dependents explicitly recite DSPC/cholesterol/MPEG-2000-DSPE and sucrose octasulfate salt gel/precipitate state |
Follow-on must avoid identical formulation or equivalently define a different nanoparticle system |
| PK/clinical bridging |
Exposure profile targets (AUC/Cmax/half-life) |
Multiple dependents lock exposure ranges and specific values |
A different formulation that shifts PK may exit literal AUC/Cmax windows |
| Method-of-use |
Regimen timing and combination dosing |
Core claims require q2-week administration and combination with 5-FU + leucovorin |
A regimen change can evade if it breaks the method claim’s dosing structure or patient eligibility criteria |
| Biomarker/gene restriction |
Genotype-based selection (UTG1A1*28) |
Multiple independent claim versions require “not homozygous” |
A label that reframes population or uses opposite genotype inclusion can avoid literal genotype limits |
How to interpret “landscape leverage”
US 9,717,724 is not “just” about a regimen. It is about a regimen plus:
- carrier identity (lipid chemistry, vesicle scale),
- drug loading state (sucrose octasulfate salt, gelated/precipitated),
- in vivo performance (AUC/Cmax/half-life),
- and patient selection (UTG1A1*28 not homozygous).
That combination makes it harder for a follow-on to avoid infringement through minor changes in dosing or infusion time alone.
Where are the main vulnerability points for a generic or follow-on?
Based on the claim language you provided, the easiest “escape valves” (in a freedom-to-operate sense) are those that break literal capture on at least one required element:
-
*UTG1A128 eligibility**
- Claims 1 and 11 include the “not homozygous” restriction. A different patient selection strategy can avoid those claims, but claim 21/16 pathways can still remain.
-
PK window mismatch
- Exact or ranged constraints on AUC0-∞ (1091-1705) and Cmax (29-47) can be hard to hit after formulation redesign. A follow-on that shifts AUC/Cmax outside the ranges can avoid literal coverage, but again multiple claims offer alternative exposure metrics (AUC0-28 in claim 16 and half-life in claim 17/19).
-
Formulation identity and loading state
- Explicit lipid list and loading as sucrose octasulfate salt in gelated/precipitated state increases manufacturing specificity. Avoiding that may defeat dependents like claims 8/15/24.
-
Liposome size target
- Several dependents require ~110 nm. If the follow-on nanoparticle size falls outside that range but within 80-140 nm, claim 16 could still capture unless exposure is also shifted.
What would a competitor have to design to avoid all the major claim threads?
From a “design-around” standpoint, the claim set creates a multi-parameter barrier. A competitor typically has to change at least one of:
- patient selection (UTG1A1*28),
- formulation construction (lipid/PEG/loading),
- and/or the resulting PK signature (AUC/Cmax/half-life and SN-38 nonlinearity).
If the competitor keeps the same carrier and dosing and patient population, the probability of landing within the literal claim windows is high.
Key Takeaways
- US 9,717,724 is a method-of-treatment patent built around a q2-week regimen of liposomal irinotecan 70 mg/m² + (l)-leucovorin 200 mg/m² + 5-FU 2,400 mg/m² for gemcitabine-progressed metastatic pancreatic adenocarcinoma, with *UTG1A128 “not homozygous”** selection in key independent claim versions.
- The claims strongly tether infringement to the liposomal/nanoparticle formulation and PK outcomes, including ~110 nm, lipid composition (DSPC, cholesterol, MPEG-2000-DSPE), sucrose octasulfate salt loading in gelated/precipitated state, and exposure windows (AUC0-∞ 1091-1705, Cmax 29-47, plus 25.8-hour half-life and SN-38 non-linear AUC behavior).
- The landscape posture is best understood as layered claim coverage: formulation identity and PK metrics in dependents, and regimen plus patient selection in independents. Avoiding literal capture likely requires coordinated design changes that shift at least one required parameter meaningfully.
FAQs
1) Does US 9,717,724 protect only metastatic pancreatic cancer?
The independent claim language you provided includes metastatic adenocarcinoma of the pancreas (claims 1, 11, 21, 22). It also includes a broader “pancreatic cancer” framing in claim 16, tied to prior gemcitabine treatment.
2) Is UTG1A1*28 required for all coverage under the patent?
No. Claims 1 and 11 explicitly require patients *not homozygous for UTG1A128**. Claim 21’s independent text you provided does not state the genotype restriction, while claim 22 adds it. Claim 16 does not show the genotype restriction in the portion you provided.
3) What PK targets are explicitly recited?
The claim set you provided includes liposomal irinotecan AUC0-∞ targets (including 1091-1705 [h·µg/mL] and 1364 [h·µg/mL]) and Cmax targets (including 29-47 µg/mL and 37 µg/mL), plus terminal elimination half-life of 25.8 hours and an SN-38 dose-exposure relationship constraint.
4) Does the patent require a specific liposome lipid composition?
Yes, multiple dependent claims list the lipid components, including DSPC, cholesterol, and MPEG-2000-DSPE and describe the PEGylated phosphatidyl-ethanolamine component.
5) What is the most operational dosing schedule described?
Across the independent methods you provided, dosing is once every two weeks. Claim 11 and dependents specify liposomal irinotecan infusion over 90 minutes.
References
[1] United States Patent 9,717,724 (claims text as provided in the prompt).
